Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
Credit: Novartis The IV formulation is supplied as a 125mg/5mL solution in a single-dose vial and requires dilution prior to administration. The Food and Drug Administration (FDA) has approved an ...
The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...
The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness ...
cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback